Navigation Links
Interleukin Genetics to Present at G-2 Reports' Molecular Diagnostic Conference

CEO Lewis Bender Shares Vision for Genetic Testing Industry

WALTHAM, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced today that Chief Executive Officer Lewis H. Bender will speak at the Washington G-2 Reports' Business & Financial Strategies for Molecular Diagnostics conference, taking place February 2-4, 2009 in Fort Lauderdale, FL. The presentation is scheduled for Wednesday, February 4 at 8:30 a.m.

As part of his discussion, Mr. Bender will address the opportunities and challenges that exist within the genetic personalized health industry. The presentation will center on navigating genetic tests through consumer and physician channels from a regulatory, scientific and marketing standpoint, while providing a case study example to demonstrate their medical utility.

"The benefits of genetic testing across channels are significant," said Bender. "Not only can drug developers improve their probability of success in clinical trials by using genetic biomarkers to screen out non-responders, but consumers can use genetic tests to improve wellness by personalizing their diet, environment and lifestyle choices best suited for their genetic makeup."

Washington G-2 Reports' Molecular Diagnostics conference will provide expert insight and advice on how laboratories can and are successfully integrating molecular diagnostics into their business strategies, given the current regulatory business environment.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE: Alternext US: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.

SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
2. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
3. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
4. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
5. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
6. Interleukin-12 indicates survival prospects for melanoma patients
7. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
8. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
9. T cell immunity enhanced by timing of interleukin-7 therapy
10. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
11. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
Post Your Comments:
(Date:12/1/2015)... ... 01, 2015 , ... Physicians’ Education Resource®, LLC (PER®) ... announced that the first annual School of Gastrointestinal Oncology™ (SOGO™) will be held ... treatment of gastrointestinal cancers are undergoing transformational change, providing oncologists with powerful new ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Growth in ... part due to decreases in utilization of hospital and nonhospital care, according to a ... CompScope™ Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim with ...
(Date:12/1/2015)... Illinois (PRWEB) , ... December 01, 2015 , ... ... and share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ ... Society of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates ... a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they ... Society of North America (RSNA) 2015 annual meeting through December 3 in Chicago, ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... and clinical solutions for the care management and population health arenas, is pleased ... providing clinical and cost containment services, has successfully implemented the ACUITY Complete Care™ ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 /PRNewswire/ ... announced the addition of the "Medium ... Adhesives, Sealants, Lubricants, and Other Applications - ... and Forecast, 2015 - 2023" report ... ) has announced the addition of the ...
(Date:12/1/2015)... 2015   Nottingham Spirk , a leading ... publication of a free whitepaper , "The ... The whitepaper gives medical product companies, pharmaceutical manufacturers ... lucrative segment. Nottingham Spirk survey ... their own health, save money (i.e., fewer doctors, ...
(Date:12/1/2015)... Dec. 1, 2015 Array BioPharma ... that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The ... conference through a webcast on the Array ... , --> , ...
Breaking Medicine Technology: